Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression

Leukemia & Lymphoma
Meletios DimopoulosDonna M Weber

Abstract

Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the context of prospective studies. Several clinical and laboratory variables were assessed for their correlation with response and time to progression. Twenty-three (44%) patients achieved a partial response after treatment with rituximab. Previously untreated and pretreated patients had the same probability for response. Higher response rates were noted in patients with serum monoclonal protein < 40 g/l, with serum albumin > or = 35 g/l and with kappa light chain. The median time to progression for all patients was 13.8 months. A multivariate analysis indicated that elevated serum monoclonal protein levels and low serum albumin were the dominant variables associated with shorter progression. Presence of two, one or none of these adverse prognostic factors was associated with time to progression of 3.6 months, 11 months and more than 40 months, respectively. We conclude that rituximab is an effective treatment modality f...Continue Reading

References

Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosR Alexanian
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos
Jan 11, 2003·Clinical Lymphoma·Meletios A DimopoulosJohn Christakis
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BoyeA Engert

❮ Previous
Next ❯

Citations

Mar 21, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Steven AustinNick Losseff
Apr 6, 2012·Expert Review of Hematology·Pierre Morel, Giampaolo Merlini
Aug 4, 2007·British Journal of Haematology·Rafael Fonseca, Suzanne Hayman
Oct 29, 2008·Hematology/oncology Clinics of North America·Stefan Peinert, John F Seymour
Mar 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine I ChenUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosSteven P Treon
Dec 18, 2008·European Journal of Haematology·Xavier LeleuIrene M Ghobrial
Jan 4, 2018·Blood Advances·Efstathios Kastritis, Meletios A Dimopoulos
Jan 22, 2020·Leukemia & Lymphoma·Iuliana Vaxman, Morie Gertz
Sep 4, 2008·Clinical Lymphoma & Myeloma·Arun Vijay, Morie A Gertz
Apr 8, 2010·Clinical Lymphoma, Myeloma & Leukemia·Meletios A DimopoulosSteven P Treon

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.